Sertraline for Panic Disorder

Inspect the conclusion, its exact scope, the statements used to support it, and when each source was checked. This page does not add clinical advice or extend the published research beyond its stated scope.

Published assessment

Only this Treatment × Need pair is assessed here.

1 distinct published sources

Research suggests benefit in this exact scope

Published Sep 20, 2026 · revision 1

Reasoning and support

Open any source row to inspect scope and supporting text.

conclusion

The current ZOLOFT label reports three double-blind, placebo-controlled studies in adult outpatients with panic disorder. This bounded assessment does not compare every option or determine personal suitability.

DailyMed sertraline (Zoloft) label · checked Sep 20, 2026

Relationship: supports bounded conclusion

Scope: country:US

Pointer: /sections/2

Supporting passage: The effectiveness of ZOLOFT in the treatment of PD was demonstrated in three double‑blind, placebo‑controlled studies (Studies PD-1, PD-2, and PD‑3) of adult outpatients who had a primary diagnosis of PD (DSM‑III‑R), with or without agoraphobia.

Open source

Relationship source

Why this Treatment appears in the Need landscape, separate from the research conclusion.

DailyMed sertraline (Zoloft) label · checked Sep 20, 2026

Relationship: label-reported clinical studies for the Need

Scope: country:US

Pointer: /sections/2

Supporting passage: The effectiveness of ZOLOFT in the treatment of PD was demonstrated in three double‑blind, placebo‑controlled studies (Studies PD-1, PD-2, and PD‑3) of adult outpatients who had a primary diagnosis of PD (DSM‑III‑R), with or without agoraphobia.

Open source

See something wrong? Tell us. Your note is private. We check sources before we change this page.